drugset / Trial / NCT03791918
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Phase 3
Withdrawn
Sun Yat-sen University
Guangzhou No.12 People's Hospital · collabKaiping Central Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria
Timeline
- Start
- 2019-01-01
- Primary completion
- 2022-01-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | EADM | Unknown | — | Other |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Comparator | Lobaplatin | Small molecule | — | Other |
| Comparator | MMC | Unknown | — | Other |